The FDA has approved baloxavir marboxil (Xofluza – Shionogi/Genentech), the first polymerase acidic (PA) endonuclease inhibitor, for single-dose, oral treatment of acute uncomplicated influenza in patients ≥12 years old. Baloxavir is the first drug with a new mechanism of action to be approved for treatment of influenza in almost 20 years.
STANDARD TREATMENT — Neuraminidase inhibitors, which are active against both influenza A and B viruses, have been the drugs of choice for treatment and prophylaxis of influenza for many years. They are most effective when started within 48 hours after...
- Rivaroxaban (Xarelto) plus Aspirin for Secondary Prevention of Cardiovascular Events
- Sodium Zirconium Cyclosilicate (Lokelma) for Hyperkalemia
- Angiotensin II (Giapreza) for Septic Shock
- Clarification: Management of Opioid Withdrawal Symptoms
- IV Aprepitant (Cinvanti) for Chemotherapy-Induced Nausea and Vomiting (online only)
- Juluca - A Two-Drug Complete Regimen for HIV (online only)
- Vaccines for Travelers
- Expanded Table: Some Vaccines for Travelers (online only)
- Tickborne Encephalitis and Dengue Vaccines (online only)
The FDA has approved a new 2.5-mg formulation of the direct factor Xa inhibitor rivaroxaban (Xarelto – Janssen) for use in combination with low-dose aspirin to reduce the risk of major cardiovascular events in patients with chronic coronary artery disease (CAD) or peripheral artery disease (PAD). Rivaroxaban is the first direct oral anticoagulant to be approved for this indication. It was approved earlier for prevention and treatment of deep vein thrombosis (DVT) or pulmonary embolism (PE) and for prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation.1,2
SECONDARY PREVENTION — Most expert clinicians recommend aspirin 81-162 mg/day indefinitely for patients with atherosclerotic vascular disease (excluding those ...
